| Name | Title | Contact Details |
|---|
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
Interspond is a Trial Management Organization (TMO) that works with a network of multi therapeutic sites across the country to facilitate clinical and pharmaceutical research and trials.
Impactful healthcare provided by kind people so Western New Yorkers can achieve their dreams and goals. Quality care, regardless of ability to pay. #unstoppable
TubeWriter is a company that provides direct labeling systems and services to the life sciences industry. Their solutions print on any laboratory tube, slide or plate, and offer superior durability of print at extreme temperatures, up to 90% reduction ...
Therapeutic and Educational Services Provider